Javelin's shareholders launch enquiry into "unfair" acquisition offer
This article was originally published in Scrip
Executive Summary
Javelin Pharmaceuticals' shareholders have hired a law firm to investigate whether Myriad Pharmaceuticals' $96 million offer for the company made on December 18th is unfair.